Topics

Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

04:24 EDT 8 Oct 2019 | Pharmafile

Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate AKCEA-ANGPTL3- LRx in a deal that could generate over $1.5 billion for Akcea and its parent company Ionis Pharmaceuticals.

AKCEA-ANGPTL3- LRx is an antisense therapy designed to reduce the produce of angiopoietin-like 3 (ANGPTL3) protein in the liver, which is a key regulator of triglycerides, cholesterol, glucose and energy metabolism.

read more

Original Article: Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

NEXT ARTICLE

More From BioPortfolio on "Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...